Case Report
Psychopathology 2011;44:201–204
DOI: 10.1159/000322794
Received: February 5, 2010
Accepted after revision: November 8, 2010
Published online: March 17, 2011
Fabry’s Disease and Psychosis:
Causality or Coincidence?
S. Gairing a R. Wiest b S. Metzler a A. Theodoridou a P. Hoff a
a
b
Department of General and Social Psychiatry, Psychiatric University Hospital Zurich, Zurich, and
Institute of Diagnostic and Interventional Neuroradiology, University of Bern, Inselspital, Bern, Switzerland
Key Words
Genetics ⴢ Neuropsychological testing ⴢ Neuroimaging ⴢ
Psychoses ⴢ Psychopathology
Abstract
A 21-year-old female with Fabry’s disease (FD) presented
acute psychotic symptoms such as delusions, auditory hallucinations and formal thought disorders. Since the age of
14, she had suffered from various psychiatric symptoms
increasing in frequency and intensity. We considered the
differential diagnoses of prodromal symptoms of schizophrenia and organic schizophrenia-like disorder. Routine
examinations including cognitive testing, electroencephalography and structural magnetic resonance imaging revealed no pathological findings. Additional structural and
functional imaging demonstrated a minor CNS involvement
of FD, yet without functional limitations. In summary our examination results support the thesis that in the case of our
patient a mere coincidence of FD and psychotic symptoms
is more likely than a causal connection.
Copyright © 2011 S. Karger AG, Basel
© 2011 S. Karger AG, Basel
0254–4962/11/0443–0201$38.00/0
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
Accessible online at:
www.karger.com/psp
Introduction
Fabry’s disease (FD) is an X-linked lysosomal storage
disease, the incidence of which has been underestimated
and is likely to be as high as 1 in 3,100 male babies [1]. The
deficiency in ␣-galactosidase A results in accumulation
of glycosphingolipids in many tissues and cell types. This
process leads to progressive organ dysfunction and thus
typical clinical signs of the disease. In early stages, the
patients present with burning pain in hands and feet, hypohydrosis, abdominal pain, postprandial diarrhea and
poor growth. In later stages, life-threatening complications like renal insufficiency as well as cardiac and cerebrovascular incidents may occur. Ever since its introduction in 2001, enzyme replacement therapy has helped to
improve patients’ life expectancy and quality of life by
reducing tissue deposition and by easing clinical symptoms like pain and acroparesthesia.
These neurological symptoms are mainly held responsible for the most common psychiatric manifestation in
these patients, depressive syndromes, which are generally regarded as adjustment disorders [2–4]. Our literature research has revealed only 2 cases of patients with
FD and a concomitant psychosis which were discussed
controversially [5, 6].
Dr. Anastasia Theodoridou
Psychiatric University Hospital Zurich
Department of General and Social Psychiatry
Lenggstrasse 31, CH–8032 Zurich (Switzerland)
Tel. +41 44 384 2648, Fax +41 44 384 2506, E-Mail anastasia.theodoridou @ puk.zh.ch
Table 1. Cognitive tests
Test and reference
Domain
MWT
ZVT
FAIR
TAP phasic alertness
TAP tonic alertness
TAP divided attention
VLMT verbal learning
VLMT delayed recall
Digit span (WMS-R)
Block span (WMS-R)
Stroop test
RWT S-words
RWT animals, food
5-Point test
Trail making A and B
CKV
premorbid verbal intelligence
processing speed
attention
attention
attention
attention
verbal learning
verbal memory
verbal working memory
visuospatial working memory
attention, executive function
phonematic fluency
categorial fluency
figural fluency
speed, cognitive flexibility
executive function
Test score
on t-scale
50
39
39
36
30
26
51
47
44
56
40–50
58
45
<40
37
>40
MWT = Mehrfachwahl-Wortschatztest; ZVT = Zahlenverbindungstest; FAIR = Frankfurter Aufmerksamkeitsinventar;
TAP = Testbatterie zur Aufmerksamkeitsprüfung; VLMT = German Version of the California Verbal Learning Test, ‘Verbaler
Lern- und Merkfähigkeitstest’; WMS-R = Wechsler Memory
Scale-Revised; RWT = Regensburger Wortflüssigkeits-Test;
CKV = computerized and adapted version of the Wisconsin Card
Sorting Test, ‘Computergestütztes Kartensortierverfahren’.
We would like to present the case of a young woman
with FD and psychotic symptoms, in order to further develop this debate and answer the question of the relationship between FD and the psychotic symptoms: was it causality or coincidence?
Case Report
A 21-year-old female was admitted to the Psychiatric University Hospital of Zurich for the first time with acute psychotic
symptoms. She was in an agitated state and convinced she had to
die the same night. Further prominent symptoms included delusions of reference, persecutory delusions and auditory hallucinations. The patient had suffered from these symptoms for several
hours before she had called a friend for help, who accompanied
her to the hospital. The delusional beliefs and auditory hallucinations remitted within 24 h, leaving the patient with delusions of
reference and formal thought disorders, i.e. circumstantial thinking, loosening of associations and thought blocking. These symptoms had first occurred at the age of 16 and, although becoming
more intense and frequent, had never lasted for longer than 24 h.
Beforehand she had suffered from depressed mood and anxiety
202
Psychopathology 2011;44:201–204
for about 2 years. At the age of 15 she had become profoundly interested in Catholicism and has claimed to feel a strong connection to god ever since.
Her medical history revealed that the diagnosis of FD had been
established 9 years ago when the patient herself and her 9 siblings
were screened due to the diagnosis of FD in one of her brothers.
She had received enzyme replacement therapy with agalsidase ␣
(ReplagalTM) every fortnight and displayed only a mild phenotype
of the lysosomal storage disease. She complained about pain, acroparesthesia, hypohydrosis, abdominal pain, postprandial diarrhea and fatigue. Six of her 9 siblings were affected by FD as well,
one of her sisters suffered from similar psychiatric symptoms and
has been hospitalized once.
In the case of our patient, treatment was initiated with daily
doses of risperidone 1 mg at bedtime. An attempt to increase the
dosage gradually to 2 mg failed when the patient developed side
effects such as muscle stiffness and sedation and refused to continue the medication. Therapy was switched to aripiprazole, starting at a dosage of 5 mg in the morning. The dosage was increased
to 10 mg within a week. The patient reported an improvement of
her formal thought disorders. When developing a severe gastrointestinal infection, the patient demanded discontinuation of
aripiprazole. However, the psychiatric symptoms gradually improved over the following weeks. Difficulties in concentration
persisted.
During her stay at our hospital, additional examinations were
carried out. The results of laboratory screening and urine toxicology screen were normal. Electroencephalography (EEG) and conventional brain magnetic resonance imaging (MRI) revealed no
pathological findings.
Furthermore a battery of cognitive tests including measures
of processing speed, attention, memory and executive function
were administered when most positive symptoms had abated
and the patient was in a stable condition. As shown in table 1,
the patient’s premorbid intelligence level was estimated to be at
average level, whereas at the time of the testing mild cognitive
impairments were found in the domain of attention, processing
speed and measures of cognitive flexibility. The effects were
considered unlikely to occur due to medication as the daily dosage was low at the time of testing (aripiprazole 5 mg, lorazepam
0.75 mg).
As CNS involvement is known to be a possible major burden
in FD patients and suspected to be a possible cause for the symptoms described, our patient was subjected to structural and functional MRI including diffusion tensor imaging, arterial spin labeling, time-of-flight angiography [7] and magnetic resonance
spectroscopy. In structural MRI no abnormalities were found.
Cerebral blood flow as measured by arterial spin labeling was
symmetric and without pathological findings. In time-of-flight
angiography the diameter of the basilar artery was 2.8 mm and
thus pathological [8]. By visual inspection the cerebral arteries
were normal. In spectroscopy there was no focal reduction of
NAA or NAA/CR ratio and no asymmetry. An increase for choline by 10% was found in the left centrum semiovale. Neither lactate nor pathologic macromolecules were found. Diffusion tensor
imaging multiregion analysis revealed no focal pathological findings of fractional anisotropy and apparent diffusion coefficient
values (= 1/mean diffusivity) except for minor asymmetries found
in the centrum semiovale.
Gairing /Wiest /Metzler /Theodoridou /
Hoff
In the case of our patient we considered the differential
diagnoses of organic schizophrenia-like disorder and
prodromal symptoms of schizophrenia. The psychopathological findings were nonspecific. No hints for organic involvement were found in conventional MRI and
EEG examinations. Concerning the neuropsychological
testing, deficits in attention, working memory and executive function considered to be typical, but not pathognomonic, for schizophrenia [9] were partly found in our
patient (alertness, measures of selective and divided attention). Therefore and due to the heterogeneity of endophenotypes in schizophrenia, a clear diagnosis could not
be derived from the results of the routine examinations
conducted.
According to DSM IV and ICD 10, the psychotic syndrome is to be classified as an organic mental disorder
when a systemic disease affecting the CNS is present. On
the other hand, one may argue that typical features of a
developing schizophrenic disorder were present: increased stress vulnerability due to a family history of violence, the course of the disease with steadily increasing
frequency and intensity of symptoms over a period of several years. Retrospectively the patient may have been in
an early prodromal phase since first symptoms like depression and anxiety occurred at the age of 14. In the
course of disease, attenuated psychotic symptoms such as
hyperreligiosity and brief limited intermittent psychotic
episodes appeared. Because of the duration of delusional
and hallucinatory symptoms the diagnostic criteria for
duration of these symptoms in schizophrenia (ICD 10) or
schizophreniform disorder (DSM IV) were not met. Both
diagnostic manuals require presence of these symptoms
with a duration 64 weeks. Our patient’s syndrome meets
some of the major ultra-high-risk criteria [9] and meets
the diagnostic criteria for a late prodromal state [10].
In order to clarify the diagnosis, we collected further
structural and functional cerebral imaging results. Altogether, these examinations revealed mild affection of the
brain, most likely due to FD. The most common involvement of the CNS in FD is cerebral vasculopathy caused by
deposition of neutral glycosphingolipids in the vascular
endothelium [11]. The mechanical weakening of the vessel
wall caused by these depositions frequently results in dilatation and tortuosity of larger vessels [12]. Concerning the
macroangiopathic analysis conducted by time-of-flight
angiography, the basilar artery diameter of 2.8 mm in our
patient was pathological: Fellgiebel et al. [8] had found the
mean basilar artery diameter to be significantly enlarged
in women with FD compared to women of a normal control group (patients 3.0 mm, SD 0.33 mm; controls 2.4 mm,
SD 0.33 mm, p ^ 0.0005). Currently chronic cerebral hypoperfusion is regarded as a necessary condition for the
development of white matter lesions [13, 14]. The prevalence of acute cerebral hypoperfusion as in ischemic stroke
and transient ischemic attacks is significantly higher in
FD patients and a major form of disease [15]. Moreover,
autopsy studies have shown cerebral glycolipid deposition
of uncertain clinical significance in specific neuronal
populations [16, 17]. In regard to CNS manifestations, the
effect of enzyme replacement therapy on white matter lesions and on the prevalence of ischemic cerebrovascular
events has not yet been demonstrated. Restricted access of
infused enzyme to the vascular system beyond the endothelial cells [18] is likely to reduce potential clinical effects
on CNS involvement. In our patient, asymmetric findings
in the centrum semiovale in choline measurement in magnetic resonance spectroscopy hint at an ongoing neurodegenerative process. As no microangiopathic changes were
found in this region, this may be a result of accumulation
of neutral glycosphingolipids.
Altogether, the imaging findings demonstrated a minor CNS involvement with vessel dilatation and neurodegenerative findings in the right centrum semiovale, possibly due to glycolipid deposition. In a previous report on
psychosis in a patient with FD, brain MRI had revealed
small hyperintense spots in the right thalamus, midbrain
and corona radiata on T2-weighted imaging. The fact that
these lesions had been absent in previous scans was taken
as a hint for a connection between psychotic symptoms
and thalamic lesions due to FD [6]. In such cases, where
the connection between the lesions and clinical symptoms is plausible, the diagnosis of organic schizophrenialike disorder seems to be justified. In our patient, however, the pathologic findings had not yet resulted in functional limitations associated with schizophreniform
disorder or schizophrenia.
In summary, the patient’s symptoms were unlikely to
be of predominantly organic origin although mild CNS
involvement of FD is present. The categorical diagnostic
systems do not provide a differentiated diagnostic approach to such a potentially multifactorial case. The future development of these systems towards a dimensional
model allowing for multiple causes and psychopathologic
dimensions would add to a more facetted understanding
and personalized treatment of such cases. In summary,
our examination results support the hypothesis that a
mere coincidence of FD and psychotic symptoms in this
case is more likely than a causal connection.
Morbus Fabry and Psychosis
Psychopathology 2011;44:201–204
Discussion
203
References
1 Spada M, Pagliardini S, Yasuda M, Tukel T,
Thiagarajan G, Sakuraba H, Ponzone A,
Desnick RJ: High incidence of later-onset
Fabry disease revealed by newborn screening. Am J Hum Genet 2006;79:31–40.
2 Grewal RP: Psychiatric disorders in patients
with Fabry’s disease. Int J Psychiatry Med
1993;23:307–312.
3 Sadek J, Shellhaas R, Camfield CS, Camfield
PR, Burley J: Psychiatric findings in four female carriers of Fabry disease. Psychiatr
Genet 2004;14:199–201.
4 Muller MJ, Fellgiebel A, Scheurich A,
Whybra C, Beck M, Muller KM: Recurrent
brief depression in a female patient with Fabry disease. Bipolar Disord 2006;8:418–419.
5 Liston EH, Levine MD, Philippart M: Psychosis in Fabry disease and treatment with
phenoxybenzamine. Arch Gen Psychiatry
1973;29:402–403.
6 Shen YC, Haw-Ming L, Lin CC, Chen CH:
Psychosis in a patient with Fabry’s disease
and treatment with aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:
779–780.
204
View publication stats
7 McGorry PD, Nelson B, Amminger GP,
Bechdolf A, Francey SM, Berger G, RiecherRossler A, Klosterkotter J, Ruhrmann S,
Schultze-Lutter F, Nordentoft M, Hickie I,
McGuire P, Berk M, Chen EY, Keshavan MS,
Yung AR: Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry 2009; 70:
1206–1212.
8 Fellgiebel A, Keller I, Marin D, Muller MJ,
Schermuly I, Yakushev I, Albrecht J, Bellhauser H, Kinateder M, Beck M, Stoeter P:
Diagnostic utility of different MRI and MR
angiography measures in Fabry disease.
Neurology 2009;72: 63–68.
9 McGorry PD, Yung AR, Phillips LJ: The
‘close-in’ or ultra high-risk model: a safe and
effective strategy for research and clinical intervention in prepsychotic mental disorder.
Schizophr Bull 2003;29:771–790.
10 Hafner H, Maurer K, Ruhrmann S, Bechdolf
A, Klosterkotter J, Wagner M, Maier W,
Bottlender R, Moller HJ, Gaebel W, Wolwer
W: Early detection and secondary prevention of psychosis: facts and visions. Eur Arch
Psychiatry Clin Neurosci 2004;254:117–128.
11 Zarate YA, Hopkin RJ: Fabry’s disease. Lancet 2008;372:1427–1435.
Psychopathology 2011;44:201–204
12 Mitsias P, Levine SR: Cerebrovascular complications of Fabry’s disease. Ann Neurol
1996;40:8–17.
13 Pantoni L, Garcia JH: Pathogenesis of leukoaraiosis: a review. Stroke 1997; 28:652–659.
14 Bisschops RH, van der Graaf Y, Mali WP, van
der Grond J: High total cerebral blood flow
is associated with a decrease of white matter
lesions. J Neurol 2004;251:1481–1485.
15 Mehta A, Ginsberg L: Natural history of the
cerebrovascular complications of Fabry disease. Acta Paediatr Suppl 2005; 94: 24–27;
discussion 9–10.
16 deVeber GA, Schwarting GA, Kolodny EH,
Kowall NW: Fabry disease: immunocytochemical characterization of neuronal involvement. Ann Neurol 1992; 31:409–415.
17 Kaye EM, Kolodny EH, Logigian EL, Ullman
MD: Nervous system involvement in Fabry’s
disease: clinicopathological and biochemical
correlation. Ann Neurol 1988;23:505–509.
18 Schiffmann R, Rapkiewicz A, Abu-Asab M,
Ries M, Askari H, Tsokos M, Quezado M:
Pathological findings in a patient with Fabry
disease who died after 2.5 years of enzyme
replacement. Virchows Arch 2006; 448: 337–
343.
Gairing /Wiest /Metzler /Theodoridou /
Hoff